Clinical trials: Vitamin D Insufficiency
Chronic Kidney Disease Stage 3 and 4
Vitamin D Supplement Study for Stage Three and Four Chronic Kidney Disease (CKD) Patients
The purpose of this study is to examine the effectiveness of vitamin D3 versus vitamin D2 in raising vitamin D levels and suppressing parathyroid hormone levels in patients with kidney disease who are not on dialysis.
- Trial name
- UPGRADE (NCT01173848)
- Testing
- Ergocalciferol, Cholecalciferol
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- The Cleveland Clinic
Vitamin D Status, Healthy
Comparison of the Efficacy of Calcium-cholecalciferol Foodstuffs and Calcium-cholecalciferol Supplement
This study is conducted in two phases. At the first phase, the prevalence of vitamin D insufficiency in primary school-children in Tehran is determined during the cold seasons of 2008.
- Trial name
- NCT00864539
- Testing
- fortified milk, plain milk, fortified orange juice
- Volunteers
- 585 people, healthy volunteers welcome
- Sponsor
- National Nutrition and Food Technology Institute
Chronic Renal Insufficiency, Proteinuria
The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease
A randomized clinical trial to determine if vitamin D repletion in CKD (Chronic Kidney Disease) patients with low vitamin D levels will decrease proteinuria, a marker of kidney damage.
- Trial name
- NCT01029002
- Testing
- Vitamin D
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Albert Einstein College of Medicine
Chronic Kidney Disease
Metabolic Effects of Paricalcitol
The purpose of this study is to determine if treatment with paricalcitol, an active form of vitamin D, has beneficial effects on metabolic abnormalities in people with stage 3-4 Chronic Kidney Disease (CKD).
- Trial name
- NCT01003275
- Testing
- Paricalcitol
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Washington
Secondary Hyperparathyroidism Due to Renal Causes, Chronic Kidney Diseases
Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI
Safety, Efficacy, PK and PD of CTAP101 (calcifediol) ER Capsules for SHPT in HD Patients VDI
- Conditions
- Secondary Hyperparathyroidism Due to Renal Causes, Chronic Kidney Diseases, Vitamin D Deficiency, Stage 5 Chronic Kidney Disease
- Trial name
- NCT03602261
- Testing
- Calcifediol Oral Capsule
- Where
- 18 sites in United States
- Volunteers
- 44 people
- Sponsor
- OPKO Health, Inc.
End-stage Renal Disease
Vitamin D and Arteriovenous Fistulae
Patients requiring hemodialysis following kidney failure need a form of dialysis vascular access in order to undergo the dialysis procedure. Dialysis vascular access dysfunction is an enormous clinical problem.
- Trial name
- NCT00912782
- Testing
- Vitamin D3
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Emory University
Chronic Kidney Disease, Secondary Hyperparathyroidism
Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D
Evaluates the effectiveness of on-label Paricalcitol versus Cinacalcet with Low-Dose Vitamin D.
- Conditions
- Chronic Kidney Disease, Secondary Hyperparathyroidism, Hemodialysis
- Trial name
- IMPACT SHPT (NCT00977080)
- Testing
- Paricalcitol, Cinacalcet
- Where
- 83 sites in United States, Czechia and 10 more
- Volunteers
- 272 people
- Sponsor
- Abbott
Healthy
Defining Vitamin D Insufficiency in School Age Children: A Randomized Placebo Controlled Trial of Vitamin D3
The study objective is to characterize the threshold levels of serum 25-hydroxyvitamin D for the definition of vitamin D insufficiency in 8-14 year old African American and Caucasian children.
- Trial name
- Vitamin D RCT (NCT00732758)
- Testing
- Vitamin D3 1000 IU
- Where
- United States
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Coronary Artery Disease, Chronic Kidney Disease
Effect of Vitamin D Supplement on Inflammation Markers in High-Risk Cardiovascular Patients With Chronic Kidney Disease
The purpose of this study is to determine if vitamin D supplementation changes the results of certain tests associated with inflammation in the body using an oral, synthetic form of vitamin D called paricalcitol.
- Conditions
- Coronary Artery Disease, Chronic Kidney Disease, Hypovitaminosis D, Secondary Hyperparathyroidism
- Trial name
- VINCA-CKD (NCT01012414)
- Testing
- paricalcitol
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Thomas Jefferson University
Chronic Kidney Disease, Vitamin D Deficiency
Vitamin D and Coronary Calcification Study
Patients with chronic kidney disease (CKD) have a higher mortality rate than the general population, with cardiovascular disease (CVD) accounting for approximately 50% of deaths.
- Conditions
- Chronic Kidney Disease, Vitamin D Deficiency, Coronary Calcification, Disorders of Calcium and Bone Metabolism
- Trial name
- VCOR (NCT00752102)
- Testing
- Calcitriol (Rocaltrol®), Paricalcitol
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Joslin Diabetes Center
Chronic Kidney Disease
Vitamin D Repletion in Chronic Kidney Disease
The reason for doing this research is that people with kidney disease often suffer from heart disease. Why this happens is not fully known.
- Trial name
- NCT00772772
- Testing
- Vitamin D3
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
Vitamin D Deficiency
Improving the Understanding of the Response to Vitamin D Supplementation
It is the investigators hypothesis that the current method of evaluating vitamin D status, measuring circulating 25-hydroxy vitamin D is not providing the full metabolic picture, and is therefore inadequate.
- Trial name
- NCT01465178
- Testing
- cholecalciferol
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Chronic Kidney Disease, Vitamin D Deficiency
Cholecalciferol (Vitamin D3) Therapy in Chronic Kidney Disease (CKD) Subjects
This is a 12 week pilot and feasibility study with an enrollment goal of 30 subjects. Half of the subjects will be randomized to vitamin D3 and the other half will receive a placebo.
- Trial name
- NCT00427037
- Testing
- Cholecalciferol
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Atlanta VA Medical Center
Vitamin D Deficiency, Accidental Falls
Improving Vitamin D Status in Home-bound Elders
In the past two decades, the role of vitamin D has extended beyond bone health to encompass a wide range of biological activities important to physical function in older adults.
- Trial name
- MOW VitD (NCT01410084)
- Testing
- Vitamin D3, Vitamin E
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Wake Forest University Health Sciences
Arterial Dysfunction, Chronic Kidney Disease
Vitamin D and Arterial Function in Patients With Chronic Kidney Disease
The purpose of this study is to determine whether nutritional (cholecalciferol) or active vitamin D (calcitriol) supplementation improves vascular endothelial function in patients with stage IIIB and IV chronic kidney disease…
- Trial name
- NCT01384539
- Testing
- Cholecalciferol, Calcitriol
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- University of Colorado, Denver
Secondary Hyperparathyroidism Due to Renal Causes, Vitamin D Insufficiency
Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency
An Open-Label, Repeated-Dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Oral CTAP101 Capsules, Immediate- Release (IR) Calcifediol, High-Dose Cholecalciferol, and Paricalcitol Plus Low-Dose Cholecalciferol in…
- Conditions
- Secondary Hyperparathyroidism Due to Renal Causes, Vitamin D Insufficiency, CKD Stage 3, CKD Stage 4
- Trial name
- NCT03588884
- Testing
- Calcifediol Oral Capsule, Calcifediol Oral Product, Cholecalciferol
- Where
- 3 sites in United States
- Volunteers
- 69 people
- Sponsor
- OPKO Health, Inc.
End Stage Renal Disease
Effect of Lanthanum Carbonate in Patients Previously Treated With Calcium-based Phosphate Binder Therapy
To assess the percentage of patients on lanthanum carbonate, that achieve Kidney Disease Outcome Quality Initiative (KDOQI) guideline suggested values for serum phosphorous in patients previously treated with calcium-based…
- Trial name
- NCT01130831
- Testing
- Lanthanum carbonate
- Where
- 31 sites in Germany
- Volunteers
- 66 people
- Sponsor
- Shire
Secondary Hyperparathyroidism, Chronic Kidney Disease
Study to Assess Patient Management Practices and Quality of Life With Paricalcitol Capsules in the Treatment of Secondary Hyperparathyroidism in Stage 3-5 Chronic Kidney Disease Patients Not Yet on Dialysis
Paricalcitol capsules (Zemplar®) received marketing authorization in Sweden in late 2007 for the prevention and treatment of secondary hyperparathyroidism in patients with Stage 3 \& 4 Chronic Kidney Disease (CKD).
- Trial name
- CAPITOL (NCT01265992)
- Where
- 10 sites in Sweden
- Volunteers
- 50 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Chronic Kidney Disease, Endothelial Dysfunction
Study of Protective Effects of Paricalcitol on Inner Layer of Vessels and Its Protective Effect on Inflammation
The study is about possible protective effects of paricalcitol (Zemplar) upon inflammation, blood pressure and kidney function. Kidney Inflammation occurs when white blood cells become abnormally stimulated and accumulate in the…
- Conditions
- Chronic Kidney Disease, Endothelial Dysfunction, Inflammation, Hypertension
- Trial name
- NCT00428246
- Testing
- paricalcitol
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Indiana University
Chronic Kidney Disease, Secondary Hyperparathyroidism
Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)
This study will investigate how the levels of a repeat dose of CTAP101 changes in the body over time (pharmacokinetics, PK) and how CTAP101 affects other mineral and hormonal balances (pharmacodynamics, PD) in patients with…
- Conditions
- Chronic Kidney Disease, Secondary Hyperparathyroidism, Vitamin D Insufficiency
- Trial name
- NCT01219855
- Testing
- Cohort 1 CTAP101 Capsules- 60µg, Cohort 1 CTAP101 Capsules - 90µg, Cohort 1 Matching Sugar Capsule
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- OPKO Health, Inc.